Talk:Valsartan

From WikiProjectMed
Jump to navigation Jump to search

Untitled

The Valsartan page is already being vandalized. cf. 'to give cancer after a heart attack' phrase in first para. You might want to lock it down for the time being Johnnyrev (talk) 23:40, 16 July 2018 (UTC)[reply]

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Valsartan18, Llaw18, Jps18, Evanescerovalsartan18. Peer reviewers: Yamahaguy17, RxDream17, ChemERx17, LilSteps 17.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 12:14, 17 January 2022 (UTC)[reply]

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 27 August 2019 and 13 December 2019. Further details are available on the course page. Student editor(s): Nrich1996, Razmusj1.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 12:14, 17 January 2022 (UTC)[reply]

MI Controvery

Could somebody with more medical experience please comment on the current state of this MI controversy? As a pharmacy student, I was never made aware of this controversy before and see that ARBs are still considered first line in HTN and alternative to ACEi in other indications. I found some meta-analyses that find that ARBs do not cause additional MI or other effects. However, there is controversy regarding the efficacy of ARBs when compared to ACEi simply due to the lack of clinical studies. [1][2]

Because I don't have experience in the matter and only did a cursory pubmed search on the topic, I did not feel justified in adding it to wikipedia without some feedback, especially because I may be biased in the manner due to what my educational background taught me. Thanks! Zileu (talk) 18:27, 3 November 2014 (UTC)[reply]

References

  1. ^ Bangalore, S.; Kumar, S.; Wetterslev, J.; Messerli, F. H. (26 April 2011). "Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials". BMJ. 342 (apr26 2): d2234–d2234. doi:10.1136/bmj.d2234.
  2. ^ Volpe, Massimo; Tocci, Giuliano; Sciarretta, Sebastiano; Verdecchia, Paolo; Trimarco, Bruno; Mancia, Giuseppe (May 2009). "Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials". Journal of Hypertension. 27 (5): 941–946. doi:10.1097/HJH.0b013e32832961ed.

November 2015 Edits

Hi all, this is Group 18 from CP133 2015 at UCSF School of Pharmacy. Some edits we have made:

  1. expanding the side effects to include percentages in both heart failure and hypertension
  2. expanding the mechanism of action section
  3. removed possibly unreliable details in the economics section and updated the section with details from the Novartis 2010 report
  4. edited certain words (patient --> person) to improve readability
  5. updated the link for the Canadian labeling regarding breast feeding — Preceding unsigned comment added by Valsartan18 (talk • contribs) 07:16, 5 November 2015 (UTC)[reply]

Recall on generica

I am interested to include a small paragraph on the recent valsartan generica recall in Europe (EMA) and the US. Since we are writing for the public, this would be of great interest. But it relates to the manufacturing of the the drug, I can't go too much into detail. But the recall is quite important due to the N-Nitrosodimethylamine impurity from a changed manufacturing process. Osterluzei (talk) 02:42, 14 July 2018 (UTC)[reply]

Health Policy Feedback

The current page is a good improvement!

  1. Neutral point of view: Yes
  2. Verifiable: Yes
  3. Comments:
    1. Side effects: looks much better than previous. Needs some reformatting for consistency (some are bullets, others not), remember we are writing for the public so study details (if included) should be easily understood and links provided, add information about dry cough (very common)
    2. MOA: more wiki links, balance information with readability (public has diverse health literacy)
    3. In general: good job adding citations, use more wiki links, keep writing at lay level, be concise where appopriate, include citations in introduction.

Yamahaguy17 (talk) 06:42, 9 November 2015 (UTC)[reply]

Retrieved from "https://mdwiki.org/wiki/Talk:Valsartan"